Clinical trials: Oral Phase
Healthy
Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ZYIL1 Following Oral Administration in Healthy Volunteers
ZYIL1 is a novel oral selective NLRP3 inflammasome inhibitor which prevents NLRP3-induced ASC oligomerization, thus inhibiting NLRP3 inflammasome pathway.
- Trial name
- NCT04731324
- Testing
- ZYIL1 capsule
- Where
- India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Zydus Lifesciences Limited
Insulin Resistance
A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin Resistance
This Phase 2a study is designed to evaluate the safety, tolerability, effectiveness, and pharmacokinetics (PK) of TLC-3595 in subjects with insulin resistance.
- Trial name
- NCT05665751
- Testing
- TLC-3595 Dose 1, TLC-3595 Dose 2
- Where
- 4 sites in New Zealand
- Volunteers
- 76 people
- Sponsor
- OrsoBio, Inc
Follicular Lymphoma
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
This study evaluates the safety and efficacy of combining the EZH2 inhibitor tazemetostat with rituximab in R/R FL subjects previously treated with at least 2 standard prior systemic treatment regimens where at least 1…
- Trial name
- NCT04762160
- Testing
- Tazemetostat, Rituximab
- Where
- 20 sites in United States
- Volunteers
- 5 people
- Sponsor
- Epizyme, Inc.
Behçet Disease
Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease
The aim of this study is to estimate the efficacy of apremilast compared to placebo in the treatment of oral ulcers in pediatric participants from 2 to < 18 years of age with oral ulcers associated with Behçet's disease (BD)…
- Trial name
- BEAN (NCT04528082)
- Testing
- Apremilast
- Where
- 27 sites in France, Greece and 6 more
- Volunteers
- 60 people
- Sponsor
- Amgen
Metastatic Pancreatic Ductal Adenocarcinoma
Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC
This is a Phase 1, open label, multi center, multiple dose, dose escalation, safety, pharmacokinetic and pharmacodynamic study of palbociclib in combination with nab-P, in sequential cohorts of adult patients with mPDAC, with MTD…
- Trial name
- NCT02501902
- Testing
- Palbociclib, Nab-Paclitaxel
- Where
- 26 sites in United States, Spain
- Volunteers
- 76 people
- Sponsor
- Pfizer
Healthy
Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male Subjects
This will be a Phase 1, open-label, nonrandomized, single-dose study in healthy male subjects to evaluate the Absorption, Metabolism, and Excretion of Poziotinib following a single oral dose of [14C]-poziotinib to healthy male…
- Trial name
- NCT04436562
- Testing
- [14C]-Poziotinib
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Spectrum Pharmaceuticals, Inc
Healthy Adults
A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib
A Phase 1, Open-label, Multiple-dose, One-sequence Crossover Study to Investigate the Effect of Repeated Oral Doses of a Strong CYP2C8 Inhibitor on the Steady-state Pharmacokinetics of Adagrasib in Healthy Adult Subjects
- Trial name
- NCT05868356
- Testing
- Treatment A, Treatment B
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Mirati Therapeutics Inc.
Advanced Cancer, Refractory Cancer
A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients
The Epidermal Growth Factor Receptor (EGFR) is a validated target for the treatment of cancer, and agents targeting EGFR such as erlotinib (Tarceva®) are approved by the FDA for treatment of various solid tumors.
- Trial name
- NCT00551850
- Testing
- AV-412
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Major Depressive Disorder
Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects
The purpose of the study is to investigate the effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects
- Trial name
- SUVN-911 (NCT03551288)
- Testing
- SUVN-911
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Suven Life Sciences Limited
Japanese Premenopausal Healthy Adult Women
A Food Effect Study of TAK-385 Final Formulation
The purpose of this study is to evaluate food effects on the pharmacokinetics of a single oral dose of TAK-385 in Japanese premenopausal healthy adult women.
- Trial name
- NCT02792062
- Testing
- TAK-385 40 mg
- Where
- Japan
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Takeda
Plaque Psoriasis
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.
This study will evaluate the effects of an experimental (being tested) study drug called apremilast. Apremilast works by lowering some of the chemicals that affect psoriasis and therefore improves the symptoms of psoriasis.
- Trial name
- ESTEEM 2 (NCT01232283)
- Testing
- Apremilast, Topical or Phototherapy Therapy
- Where
- 46 sites in United States, Austria and 7 more
- Volunteers
- 413 people
- Sponsor
- Amgen
Healthy
A Phase 1, Bioequivalence Study of SYR-472 25mg and 50mg Tablets
The purpose of this study is to investigate the bioequivalence of 2 tablets of SYR-472 25 milligram (mg) and 1 tablet of SYR-472 50 mg administered to healthy adult males.
- Trial name
- NCT02372097
- Testing
- SYR-472
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Takeda
Hypogonadism
Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men
The purpose of this pharmacokinetic study is to determine whether oral testosterone (T) ester formulations can be used effectively to treat men with low testosterone.
- Trial name
- NCT00695110
- Testing
- Oral testosterone undecanoate (TU) (300 mg T equivalents/dose), Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose), Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food)
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Clarus Therapeutics, Inc.
Trigeminal Neuralgia
Botulinum Toxin Type A for Injection (HengLi®) in the Treatment of Trigeminal Neuralgia
To evaluate the efficacy of different dosing regimens of Botulinum Toxin Type A for Injection (HengLi®) in the treatment of trigeminal neuralgia (TN), so as to determine the optimal dosing regimen of the best administration…
- Trial name
- NCT06410859
- Testing
- Botulinum Toxin Type A for Injection,also known as "HengLi®"
- Where
- China
- Volunteers
- 240 people
- Sponsor
- LKGS_277
Prevention of Ischemic Stroke, Acute Non-cardioembolic Ischemic Stroke
A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the last 72 hours had: an acute stroke due to a blood clot that formed outside the…
- Conditions
- Prevention of Ischemic Stroke, Acute Non-cardioembolic Ischemic Stroke, High-risk Transient Ischemic Attack
- Trial name
- OCEANIC-STROKE (NCT05686070)
- Testing
- Asundexian (BAY2433334)
- Where
- 741 sites in United States, Argentina and 35 more
- Volunteers
- 12,327 people
- Sponsor
- Bayer
Thymic Carcinoma
Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma
The intent of the study is to assess the antitumor activity of PHA-848125AC as second-line treatment in patients with recurrent or metastatic, unresectable thymic carcinoma previously treated with chemotherapy.
- Trial name
- NCT01011439
- Testing
- Milciclib Maleate
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 72 people
- Sponsor
- Tiziana Life Sciences LTD
Prevention of Venous Thrombosis After TKA
Clinical Study on the Efficacy and Safety of Multiple Oral Administrations of SHR2285 Tablets in Patients Undergoing Elective Total Knee Arthroplasty
This study is a multi-center, randomized, open-label, double-blind, positive-controlled phase II clinical study evaluating the efficacy and safety of different doses of SHR2285 tablets vs.
- Trial name
- NCT05203705
- Testing
- SHR2285 tablet, Enoxaparin
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Healthy Subjects (HS), Obese Adult Participants at Risk of Cardiovascular Disease
A Phase 1, Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISM8969
This is a single center, phase 1, randomized, double-blind, placebo-controlled sequential study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending oral doses of ISM8969…
- Trial name
- NCT07581431
- Where
- Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- InSilico Medicine Hong Kong Limited
Gastroesophageal Reflux Disease (GERD)
A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
Gastroesophageal reflux disease (GERD) is caused by food or acid coming up from the stomach into the esophagus, repeatedly. The esophagus is the tube that carries food and liquids from the mouth to the stomach.
- Trial name
- NCT02616302
- Testing
- Dexlansoprazole
- Where
- 18 sites in United States, Canada and 3 more
- Volunteers
- 71 people
- Sponsor
- Takeda
Advanced Oral and Maxillofacial Malignant Tumors
rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors
This is multicenter, open-label, randomized, active-controled, phase IV study of local direct intra-tumor injection of rAd-p53 monotherapy, with concurrent chemotherapy , or combination with surgery for treatment of advanced oral…
- Trial name
- rAd-p53 (NCT00902083)
- Testing
- p53 gene with surgery, surgery, p53 with chemotherapy
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Shenzhen SiBiono GeneTech Co.,Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.